US Pat. No. 11,064,708

PROCESS TO PRODUCE SAFE PASTEURIZED SHRIMP AND OTHER SHELLFISH OF HIGH SENSORY QUALITY AND EXTENDED REFRIGERATED SHELF-LIFE


1. A method of producing a pasteurized, shrimp food product having an extended shelf life under refrigeration conditions, said method consisting essentially of the steps:pre-cooking uncooked shrimp to a first, selected, internal, pre-cooking temperature that is within the range of 185°-190° F. for a time sufficient to coagulate proteins in the shrimp to obtain pre-cooked shrimp;
immediately cooling the pre-cooked shrimp with a cold brine containing 1.25-2 wt % salt to a temperature that is about 40° F. or less and that is sufficiently low to stop the cooking process and produce cooled shrimp;
rinsing said cooled shrimp with a 1.25-2 wt % brine rinsing solution to remove any coagulated proteins released during the pre-cooking step;
packaging the cooled, rinsed shrimp in soft, semi-rigid, or rigid containers that are conducive to rapid heat penetration and suitable to withstand pasteurization temperatures;
filling the semi-rigid or rigid containers of cooled, rinsed, shrimp with a packing brine in an amount sufficient to submerge the cooled, rinsed, shrimp completely, or filling the soft containers with cooled, rinsed shrimp;
seaming or sealing the soft, semi-rigid or rigid containers of cooled, rinsed, shrimp;
pasteurizing the soft, semi-rigid or rigid containers of cooled, rinsed, shrimp by heating the packaged shrimp to a pasteurizing temperature that is within the range of 185°-190° F. and said pasteurizing temperature is not higher than said internal pre-cooking temperature to avoid the release of protein from the packaged shrimp, said pasteurizing step occurring for a time sufficient to achieve control of nonproteolytic C. botulinum type B for 9-18 months under refrigeration conditions; and
immediately cooling the pasteurized, packaged, shrimp by immersing the pasteurized, packaged, shrimp containers in a cold water bath to stop pasteurization and produce a packaged, pasteurized, fresh, shrimp product that is stable for about 9-18 months when stored at refrigeration conditions of 32°-40° F.

US Pat. No. 11,065,222

DIAGNOSTIC ASSAY AND TREATMENT FOR PREECLAMPSIA

ASTON UNIVERSITY, Birmin...


1. A kit comprising (a) an assay for sFlt-1, (b) an assay for one or more heme breakdown products, and (c) instructions for treating pre-eclampsia in a pregnant host animal characterized by having a threshold ratio of sFlt-1 to the one or more heme breakdown products.
US Pat. No. 11,066,517

PROCESSES FOR PRODUCING FLUORINATED ETHER COMPOUNDS

AGC Inc., Chiyoda-ku (JP...


10. A process for producing a fluorinated ether compound, which comprises obtaining a compound represented by the formula (2) by the process for producing a fluorinated ether compound as defined in claim 1, and reacting the compound represented by the formula (2) with a compound represented by the following formula (6) to obtain a compound represented by the following formula (1):HSiR2nL3-n??(6)
Rf(CF2)a—C(?O)N(—R1CH2CH2SiR2nL3-n)2??(1)
wherein R2 is a monovalent hydrocarbon group,L is a hydrolysable group, and
n is an integer of from 0 to 2.


US Pat. No. 11,065,223

ANTIMICROBIAL COMPOSITIONS AND USES THEREOF

Board of Regents, The Uni...


1. An antimicrobial composition comprising: from about 0.5% to about 3% (w/w) of a polygalacturonic acid mixture and from greater than 0.1% to about 5% (w/w) of a C6-12 fatty acid; wherein the ratio of the polygalacturonic acid mixture consists of esterified polygalacturonic acid and de-esterified polygalacturonic acid in an amount of at least about 50% de-esterified polygalacturonic acid.
US Pat. No. 11,064,710

METHOD OF MAKING DAIRY COMPOSITIONS

fairlife, LLC, Chicago, ...


1. A method for producing a dairy product, the method comprising:separating milk to produce butter fat and skim milk;
ultrafiltrating the skim milk to produce a UF permeate and a UF retentate;
nanofiltrating the UF permeate to produce a NF permeate and a NF retentate;
reverse osmosis of the NF permeate to produce a RO permeate and a RO retentate;
combining a portion of the butter fat, a portion of the UF retentate, a portion of the RO retentate, and a portion of the RO permeate to produce a dairy product; and
wherein the dairy product comprises from 0.1 to 0.3 wt. % butter fat, from 6 to 9 wt. % protein, from 1 to 2 wt. % minerals, and from 2 to 5 wt. % lactose.

US Pat. No. 11,066,519

PHOTORESPONSIVE HEXAHYDROTRIAZINE POLYMERS

International Business Ma...


1. A method of patterning a substrate, comprising:forming a liquid poly(hemiaminal) material by a process, comprising:forming a reaction mixture comprising a polar solvent, paraformaldehyde, and an aminobenzene compound comprising photoreactive groups; and
heating the reaction mixture at a temperature up to 50° C.;

applying the liquid poly(hemiaminal) material to the substrate;
patterning the liquid poly(hemiaminal) material with ultraviolet (UV) light; and
curing the liquid poly(hemiaminal) material to form a cured poly(hexahydrotriazine) polymer.

US Pat. No. 11,065,225

ULTRA-LOW DOSE THC AS A POTENTIAL THERAPEUTIC AND PROPHYLACTIC AGENT FOR ALZHEIMER'S DISEASE

UNIVERSITY OF SOUTH FLORI...


1. A method for maintaining amyloid precursor protein level in a patient suffering from Alzheimer's disease, comprising administering tetrahydrocannabinol (THC) and melatonin to the patient, wherein the THC is administered in an ultra-low dose amount of from about 0.2 ?g/kg to about 0.02 mg/kg of body weight of the patient and melatonin is administered in an amount from about 0.11 mg/kg to about 1.1 mg/kg of body weight of the patient, wherein Aß production and aggregation is concurrently decreased.
US Pat. No. 11,064,968

EVALUATING ARTERIAL PRESSURE, VASOMOTOR ACTIVITY AND THEIR RESPONSE TO DIAGNOSTIC TESTS


1. A system for dynamical evaluation of at least one feature of cardiovascular activity, said system comprising:at least one accelerometer-containing sensor which is adapted for placement on the surface of an individual's torso for registering signals related to the torso surface movement respecting cardiovascular mechanical activity;
at least one acquisition module which is adapted for acquiring information from said at least one sensor; and
at least one processing module which is adapted for processing said information from said at least one sensor to evaluate at least one feature selected from arterial blood pressure in the central arteries, arterial blood-pressure wave, and pulse-transit time.

US Pat. No. 11,066,521

SILICONE ELASTOMER COMPOSITION

TESA SE, Norderstedt (DE...


1. A tin-free, room temperature curable silicone elastomer composition, wherein the uncured composition is a putty and comprises the following components:a) an end-capped base polymer, wherein the base polymer comprises a polysiloxane or mixture of polysiloxanes and has a viscosity of at least 150,000 mPa·s at 25° C., and wherein the end-capped base polymer comprises terminal di-(C2-4)alkoxy silyl groups;
b) 2 to 20 parts by weight of at least one particulate reinforcing filler for each 100 parts by weight of base polymer;
c) (85×(?F/2.8)) to (135×(?F/2.8)) parts by weight of at least one particulate non-reinforcing filler per 100 parts by weight of base polymer, wherein ?F is the mean true density (g/cm3) of the at least one particulate non-reinforcing filler; and
d) a curing catalyst consisting of one or more selected from the group consisting of: organic titanates and organic zirconates,
and wherein the composition does not contain any silicone elastomer powder.

US Pat. No. 11,064,713

SHELF STABLE RTD COCOA MILK BEVERAGE WITH IMPROVED TEXTURE/MOUTHFEEL AND METHOD OF MAKING SAME

Societe des Produits Nest...


1. A ready to drink (RTD) beverage product comprising:milk comprising casein and whey proteins, wherein a ratio between the casein and the whey proteins ranges from 75:25 to 60:40, and the milk comprises 0.5 to 2.5 wt. % milk proteins and 0.5 to 1.5 wt. % milk fat based on the weight of the RTD beverage;
added sugars up to 5 wt. % of the RTD beverage;
an acidifier selected from the group consisting of (a) lactic acid in an amount of 0.065 to 0.10 wt. % and (b) citric acid in an amount of 0.03 to 0.09 wt. % of the RTD beverage;
cocoa in a range of 0.5 to 1.5 wt. % of the RTD beverage; and
a stabilizing system comprising a high acyl gellan gum in a range of 0.01 to 0.03 wt. %, and guar gum in a range of 0.09 to 0.2 wt. % of the RTD beverage,
wherein the RTD beverage comprises casein-whey protein aggregates having a Sauter mean diameter value D[3,2] ranging from 6 to 15 ?m as measured by laser diffraction.

US Pat. No. 11,065,227

USE OF CANNABINOIDS IN THE TREATMENT OF MULTIPLE MYELOMA

GW Research Limited, Cam...


1. A method for treating multiple myeloma comprising administering to a subject in need thereof a therapeutically effective amount of a cannabis extract and a proteasome inhibitor,wherein the cannabis extract comprises the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD), wherein THC and CBD are present at greater than 98% (w/w) in the extract, and
wherein the proteasome inhibitor is bortezomib, carfilzomib or ixazomib.

US Pat. No. 11,066,522

AMPHIPHILIC POLYMER, AMPHIPHILIC POLYMER MANUFACTURING METHOD, CONTACT LENS MATERIAL INCLUDING THE AMPHIPHILIC POLYMER, AND CONTACT LENS MANUFACTURING METHOD

NATIONAL CHIAO TUNG UNIVE...


1. An amphiphilic polymer manufacturing method, comprising:(S100) providing an amphiphilic chitosan;
(S200) providing a poly(dimethylsiloxane); and
(S300) bonding the amphiphilic chitosan to the poly(dimethylsiloxane) by using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) as a catalyst.

US Pat. No. 11,065,746

METHOD FOR CLAMPED JOINT SEATING DETECTION

GENERAL ELECTRIC COMPANY,...


1. A method for filtering data derived from a process wherein the data is generated by an input of energy, the method comprising the steps of:collecting the data from the process to create a parent data set that includes data points each having a dependent variable and an independent variable associated therewith;
creating a first window of data from the parent data set, the first window spanning from a first data point to an end data point;
calculating an average of the first window of data;
comparing the average of the first window of data to a threshold value;
shifting the first window if the average has not passed the threshold value and repeating the steps of calculating and comparing;
creating a second window of data from the parent data set if the first window average has passed the threshold value, the second window being smaller than the first window and initially including the first data point of the first window and at least one data point preceding the first data point in time if the first window average has passed the threshold value;
calculating an average of the second window of data;
comparing the average of the second window of data to the threshold value;
shifting the second window if the average of the second window of data has not passed the threshold value and repeating the steps of calculating an average of the second window and comparing the average of the second window to the threshold value;
confirming that the threshold value has been reached if the second window average has passed the threshold value; and
ceasing the input of energy after confirming that the threshold value has been reached.

US Pat. No. 11,066,524

PROCESS FOR PRODUCING ALKOXYLATED POLYPHENOLS

Arkema France, Colombes ...


1. A process for producing at least one alkoxylated polyphenol comprising the following successive steps:(a) reacting at least one polyphenol, at least one alkoxylating agent and at least one catalyst in the presence of at least one alkoxylated polyphenol as a solvent,
wherein the (polyphenol)/(alkoxylated polyphenol as a solvent) weight ratio ranges from 0.05 to 0.5 and the (polyphenol)/(alkoxylating agent) weight ratio ranges from 0.15 to 0.7; and
(b) removing residual alkoxylating agent.

US Pat. No. 11,066,781

PRETREATMENT FOR APPLICATION ONTO FINISHED COTTON FABRIC

EASTERN TECH LLC, Orange...


1. An aqueous solution for the pretreatment of cotton fabrics consisting essentially of A) 40% to 70% by weight of at least one multivalent cationic salt; (B) 0.1% to 5% by weight of a blocked isocyanate crosslinking agent, wherein the isocyanate group in the blocked isocyanate crosslinking agent is a trifunctional trimethylolpropane (TMP) of toluene diisocyanate (TDI); hexamethylene diisocyanate (HDI), hydrogenated xylylene diisocyanate (H6XDI), isophorone diisocyanate (IPDI), or dicyclohexylmethane diisocyanate (H12NDI), or a combination thereof, and (C) 3% to 40% by weight of a waterborne resin, all percentages based on the weight of the aqueous solution.
US Pat. No. 11,064,716

COMPOSITION FOR COATING FROZEN CONFECTIONERY AND A PROCESS FOR MANUFACTURING SAME

Societe des Produits Nest...


1. A composition for coating a frozen confection, the composition comprising:10 to 50 wt. % dry glucose syrup with a DE (Dextrose Equivalent) from 25 to 40, a total amount of mono and di-saccharides below 10 wt. %, and a water activity below 1.0; and
35 to 70 wt. % fat.

US Pat. No. 11,065,230

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS

INSERM (INSTITUT NATIONAL...


1. A method of treating systemic mastocytosis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a XPO1 inhibitor, wherein the XPO1 inhibitor is KPT-330, KPT-276, or KPT-251.
US Pat. No. 11,065,491

VORTEX WATER FLOW GENERATOR, WATER PLASMA GENERATOR, DECOMPOSITION PROCESSOR, DECOMPOSITION PROCESSOR MOUNTED VEHICLE, AND DECOMPOSITION METHOD

HELIX CO., LTD, Kanagawa...


1. A vortex water flow generator placed between a negative electrode and a positive electrode of a water plasma generator that injects a water plasma, the water plasma becoming a jet stream by dissociating or ionizing water to form a vortex water flow having a cavity for passing are discharge generated between the negative and positive electrodes, the vortex water flow generator comprising:a cylindrical portion configured to form the vortex water flow along an inner circumference;
a middle partition protruding from the inner circumference of the cylindrical portion;
a one-end-side partition disposed in one end side of the cylindrical portion to face the negative electrode; and
the-other-end-side partition disposed in the other end side of the cylindrical portion,
wherein each of the partitions has an opening in a position including a center axis line of the cylindrical portion, the openings having different opening shapes in size,
the middle partition and the-other-end-side partition have surfaces at the negative electrode side, the surfaces being formed by tapered surfaces gradually receding from the negative electrode as close to the center axis line, and
an arc-shaped beveled portion is formed between the tapered surface and an inner circumferential surface of the opening.

US Pat. No. 11,066,526

METHOD FOR CLEAVING AMIDE BONDS

Galderma Holding SA, La ...


1. A method for cleaving amide bonds in glycosaminoglycans, the method comprising reacting a glycosaminoglycan (GAG) comprising an N-acyl amide group with hydroxylamine (NH2OH) or a salt thereof to cleave the amide bond of the amide group.
US Pat. No. 11,065,232

DIHYDROTETRABENAZINE FOR THE TREATMENT OF ANXIETY AND PSYCHOSES

ADEPTIO PHARMACEUTICALS L...


1. A method of antagonizing a dopamine D4 receptor which method comprises contacting the receptor with (?)-?-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof.
US Pat. No. 11,065,492

CONTROLLED MEDICATION DENATURING COMPOSITION AND METHOD

Okra Medical, Inc., John...


1. A composition for decomposing controlled substances, comprising:an oxidizer comprisinga permanganate, and
an isocyanurate; and

an immobilizer.

US Pat. No. 11,066,527

POLYLACTIC ACID PARTICLES AND MANUFACTURING METHOD THEREFOR

LG Hausys, Ltd.


1. Polylactic acid particles which are formed into a continuous matrix phase from a polylactic acid resin and have a particle diameter of 1 to 100 ?m,wherein the polylactic acid particles have a flow time of 20 to 30 seconds.

US Pat. No. 11,066,528

PRODUCTION OF POLYAMIDE POWDERS BY ESTER AMINOLYSIS

ARKEMA FRANCE, Colombes ...


1. A process for producing a polycondensate powder dispersion, wherein the process comprises polycondensation:i) of at least one diester and at least one diamine,
and/or
ii) of at least one amino ester,
with stirring, in a solvent that can dissolve both the diamine and the diester and/or the amino ester, but not a polyamide which forms during the polycondensation, at a temperature included in the range of from 50° C. to 120° C. such that a polycondensate powder precipitate dispersed in the solvent is obtained,
wherein the process further comprises a step of separation of the solvent and recovering a polycondensate powder, wherein the polycondensate powder comprises particles of free powder which have a spheroidal shape, a D50 measured according to ISO standard 13320-1:1999 included in the range of from 1 to 200 ?m, and which comprise traces of ester chain ends,
wherein said at least one diester is of formula:
R1—(CH2)m—R2, wherein m represents an integer ranging from 0 to 36, and R1 and R2 represent identical or different ester functions of general formula COOR3, wherein R3 represents a saturated or unsaturated, linear or branched alkyl chain of from 1 to 5 carbon atoms and/or R1—(C6H4)n—R2, wherein n represents an integer ranging from 1 to 2, and R1 and R2 represent identical or different ester functions of general formula COOR3, wherein R3 represents a saturated or unsaturated, linear or branched alkyl chain of from 1 to 5 carbon atoms;
wherein said at least one diamine is chosen from aliphatic diamines having from 6 to 12 carbon atoms;
wherein said at least one amino ester corresponds to the general formula R5—(CH2)p—R6, wherein p represents an integer ranging from 0 to 36, R5 represents a primary or secondary amine function, and R6 represents an ester function of general formula COOR7, wherein R7 represents an alkyl chain of from 1 to 5 carbon atoms;
wherein the solvent is chosen from linear alkanes, cycloaliphatic alkanes, halogenated solvents and mixtures thereof.

US Pat. No. 11,066,529

WATER-SOLUBLE MATRIX, PRE-MOLDED ARTICLE CONTAINING RESIN PARTICLES, AND METHOD FOR PRODUCING RESIN PARTICLES

DAICEL-EVONIK LTD., Toky...


1. A method for producing resin particles by bringing a pre-molded article in which resin particles are dispersed in a water-soluble matrix into contact with an aqueous solvent to elute the matrix;wherein the water-soluble matrix comprises a water-soluble polyvinyl alcohol- based resin and a saccharide; and
the water-soluble polyvinyl alcohol-based resin comprises a modified polyvinyl alcohol-based resin comprising a side chain comprising an alkyl group or alkyl chain, the alkyl group or alkyl chain comprising at least one hydroxyl group.

US Pat. No. 11,064,721

METHOD FOR PRODUCING IMMUNE ACTIVATOR AND METHOD FOR PRODUCING FOOD AND DRINK FOR IMMUNE ACTIVATION

Kazuhito Tore, Tokyo (JP...


1. A method for producing an immune activator consisting essentially of:a drying step of low-temperature dehumidification drying Gynura procumbens at 0° C. or more and 40° C. or less and at 10% or less in relative humidity; and
a cutting/pulverizing step of cutting or pulverizing the Gynura procumbens dried in the drying step while keeping at 0° C. or more and 40° C. or less.

US Pat. No. 11,065,236

PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR

Rhizen Pharmaceuticals SA...


1. A method of treating an autoimmune, respiratory and/or inflammatory disease or condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of (i) a PI3K Delta inhibitor or a dual PI3K Delta and Gamma inhibitor, and (ii) a PDE4 inhibitor, wherein(a) the PI3K Delta inhibitor is selected from (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one, (S)-2-(1-(9H-purin-6-ylamino)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one, 2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one, (S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, and pharmaceutically acceptable salts thereof,
(b) the dual PI3K Delta and Gamma inhibitor is selected from (+)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)-5-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one, (S)-3-(1-(9H-purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one, and pharmaceutically acceptable salts thereof, and
(c) the PDE4 inhibitor is selected from roflumilast and apremilast.

US Pat. No. 11,066,531

SURFACE TREATMENT LIQUID AND HYDROPHILIC TREATMENT METHOD

TOKYO OHKA KOGYO CO., LTD...


1. A surface treatment liquid comprising a resin (A) and a solvent (S),wherein the resin (A) comprises a constituent unit (a1) comprising an organic group including a quaternary ammonium cation group and having a sulfonic acid anion group at a terminal and the unit (a1) being derived from an N-substituted (meth) acrylamide,
in at least one of terminals of a main chain of the resin (A), a terminal group comprising a silanol group and/or a reactive silyl group having a group to generate a silanol group by hydrolysis is bonded,
a ratio of a mass of the resin (A) to a mass of the surface treatment liquid is less than 2 mass %, and
a pH of the surface treatment liquid is 4 or less.

US Pat. No. 11,064,723

SIX-KINGDOM ORAL NUTRITIONAL SUPPLEMENT COMPOSITION

Ancient Brands, LLC., Fr...


1. A method of supplementing nutrition in an animal or human, consisting essentially of administering, in unit dosage form, a combination of an aliquot of each of six constituents each consisting of an unrefined dried powdered substance from each of six biological kingdoms consisting of animal, plant, fungi, bacteria, protist and archaea, wherein prior to administration each of said six constituents said combination is admixed together without addition of separate excipients or fillers, further wherein after said six constituents are admixed together, said six constituents are comminuted into a reconstitutable powder, and further wherein said six constituents are fish roe, turmeric root, reishi mushroom, spirulina, Bacillus coagulans, and deep sea salt.
US Pat. No. 11,065,238

INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES

SORBONNE UNIVERSITE, Par...


1. A method for reducing ganglioside metabolism in a subject suffering from a motor neuron disease, comprising administering to the subject an inhibitor of glucosylceramide synthase (GCS), and wherein said motor neuron disease is a hereditary spastic paraplegia (HSP) selected from the group consisting of SPG11, SPG4, and SPG7, wherein said inhibitor of GCS is selected from the group consisting of an imino sugar, a ceramide analog, a carboxamide, a carbamate, a glycoside hydrolase chaperone, imiglucerase and a nucleic acid inhibitor of gene expression.
US Pat. No. 11,066,533

LOW SMOKE HALOGEN FREE FLAME RETARDANT THERMOPLASTIC ELASTOMER COMPOSITIONS

DUPONT POLYMERS. INC., W...


1. A halogen-free flame retardant polymer composition comprising:a) one or more thermoplastic elastomers; and
b) a flame retardant mixture comprising:b1) magnesium hydroxide;
b2) aluminium trihydrate;
b3) melamine cyanurate;
b4) and optionally a phosphate ester flame retardant;

wherein the one or more thermoplastic elastomers are copolyetherester elastomers;
wherein the amount of the one or more thermoplastic elastomers is from about 40 weight percent to about 80 weight percent;
wherein the sum of the amount of b1) and the amount of b2) is lower than or equal to about 20 weight percent;
and wherein the amount of the optional phosphate ester flame retardant b4), when present, is lower than or equal to 15 weight percent; and
wherein the weight percentages are based on the total weight of the flame retardant polymer composition.

US Pat. No. 11,066,534

POLYETHER-MODIFIED SILICONE COMPOSITION, SURFACTANT, FOAM STABILIZER, POLYURETHANE FOAM FORMING COMPOSITION, AND COSMETIC PREPARATION INCLUDING SAID COMPOSITION, AND METHOD FOR PRODUCING SAID COMPOSITION

DOW TORAY CO., LTD., Tok...


1. A method for manufacturing a polyether-modified silicone composition comprising:(A) at least one polyether-modified silicone represented by the general Formula (1) below:RaQbSiO(4-a-b)/2??(1)
where each R independently represents a monovalent hydrocarbon group having 1 to 30 carbon atoms and no aliphatic unsaturated bond or a silicon atom-containing organic group, each Q independently represents a polyoxyalkylene group-containing organic group represented by the general formula: —CxH2xO—(C2H4O)t1(C3H6O)t2(C4H8O)t3—Y where x, t1, t2 and t3 are numbers satisfying 2?x?8, 0?t1?60, 0?t2?50, 0?t3?50, and 2?(0+t2+t3)?110, and Y is selected from a hydrogen atom, alkyl groups having from 1 to 4 carbon atoms, and a COCH3 group, and a and b are numbers in the ranges 1.0?a?2.5 and 0.0001?b?1.5;

(B) at least one monool organic compound selected from (B1) and/or (B2) below and being a liquid at 5° C. and having one secondary alcoholic hydroxyl group but no heteroatom other than oxygen in the molecule:(B1) a glycol ether compound having a hydrogen atom substituted by an alkyl group having from 2 to 8 carbon atoms at one end, a secondary alcoholic hydroxy group at the other end, and from 2 to 3 repeating oxyalkylene units having from 2 to 4 carbon atoms,
(B2) a tripropylene glycol monomethyl ether;

wherein isopropyl alcohol (IPA) does not exceed 1 mass % of the composition; and
wherein the method comprises the steps of:
(I?) initiating and/or promoting a hydrosilylation reaction between an organic hydrogen polysiloxane and a polyether compound having an alkenyl group at one end of the molecular chain in the presence of a volatile organic solvent (B?) different from component (B); and
(II?) conducting solvent exchange of the volatile organic solvent (B?) with the monool organic compound serving as component (B).

US Pat. No. 11,066,535

BIO-BASED BINDERS INCLUDING CARBOHYDRATES AND A PRE-REACTED PRODUCT OF AN ALCOHOL OR POLYOL AND A MONOMERIC OR POLYMERIC POLYCARBOXYLIC ACID

Owens Corning Intellectua...


10. A non-woven mat comprising:a plurality of randomly oriented glass fibers in the form of a mat having a first major surface and a second major surface; and
a binder composition at least partially coating said first major surface of said mat, said binder composition comprising the reaction product of:from 1 to 40 wt. % of at least one crosslinking agent, based on the weight of the total solids in the binder composition, wherein the crosslinking agent comprises one or more of polycarboxylic acids, salts of polycarboxylic acid, anhydrides, citric acid, salts of citric acid, adipic acid, salts of adipic acid, polyacrylic acid, or salts of polyacrylic acid; and
from 10 to 60 wt. % of a pre-reacted product comprising the reaction product of a polyol with citric acid, based on the weight of the total solids in the binder composition, said polyol comprising one or more of glycerol, polyglycerol, triethanolamine, sorbitol, polyethylene glycol, propylene glycol, or ethylene glycol, and wherein said polyol and said citric acid being present in a molar ratio from about 1.5-3.0 moles polyol: 1 mole citric acid,
wherein the pre-reacted product comprises:from 5 to 25 wt. % of unreacted polyol, based on the weight of the pre-reacted product; and
less than 5 wt. % unreacted citric acid, based on the weight of the pre-reacted product.



US Pat. No. 11,065,241

PHARMACEUTICAL COMPOSITION COMPRISING QUINOLINE DERIVATIVE OR SALT THEREOF

Jiangsu Hengrui Medicine ...


1. A pharmaceutical composition, comprising:1) an active drug that is (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)-propeneamide or a pharmacologically acceptable salt thereof; and
2) cross-linked polyvinylpyrrolidone.

US Pat. No. 11,069,883

GALVANIC METAL-WATER CELL WITH NICKEL-MOLYBDENUM CATHODE

L3 Open Water Power, Inc....


1. A galvanic metal-water cell, the galvanic-metal water cell comprising:an anode;
a cathode, wherein:the cathode is a substrate having pores with a diameter under 500 microns;
the cathode comprises nickel, and
the cathode has a nickel-molybdenum coating.


US Pat. No. 11,065,242

ANTIBIOTIC SOLUTION AND METHOD OF INJECTION TO PREVENT OPHTHALMIC INFECTIONS


1. An antibiotic solution for injecting into an aqueous humor of an anterior segment of an eye for preventing endophthalmitis, the antibiotic solution consisting of:at least one antibiotic selected from the group consisting of:a. moxifloxacin in an amount of 1 mg/ml;
b. cefuroxime in an amount of 10 mg/ml; and
c. vancomycin in an amount of 10 mg/ml;

at least one carrier fluid selected from the group consisting of:a. ethyl alcohol, and
b. propylene glycol; and

a coloring agent in an amount not more than 1000 mg/ml.

US Pat. No. 11,066,538

VINYL CHLORIDE-VINYL ACETATE COPOLYMER RESIN COMPOSITION

SHIRAISHI KOGYO KAISHA, L...


1. A vinyl chloride-vinyl acetate copolymer resin composition, comprising 70 to 143 parts by mass of surface-treated calcium carbonate having calcium carbonate surface-treated with a fatty acid or a derivative thereof per 100 parts by mass of a vinyl chloride-vinyl acetate copolymer resin having a vinyl acetate content of 8 to 12% by mass,wherein the surface-treated calcium carbonate has a BET specific surface area of 10 to 40 m2/g and an amount for surface treatment ranging from 0.1×10?2 g/m2 to 0.4×10?2 g/m2 per m2/g of the BET specific surface area, and
wherein the composition is a paste sol containing 100 to 250 parts by mass of plasticizer based on 100 parts by mass of the vinyl chloride-vinyl acetate copolymer resin.

US Pat. No. 11,067,567

SPATIALLY ENCODED BIOLOGICAL ASSAYS

Prognosys Biosciences, In...


1. A method of identifying a target protein in a tissue sample, comprising:(a) delivering a plurality of probes to a tissue sample, wherein a probe of the plurality of probes comprises an antibody conjugated to an oligonucleotide having a sequence, and wherein the antibody specifically binds the target protein in the tissue sample;
(b) detecting all or a portion of the sequence of the oligonucleotide by:(i) hybridizing a probe comprising a sequence that is 100% complementary to a portion of the sequence of the oligonucleotide and a label, to the oligonucleotide; and
(ii) imaging the tissue sample after step (i) to detect the label in the tissue sample; and

(c) using the detected sequence to identify the target protein in the tissue sample.

US Pat. No. 11,065,244

METHODS OF USE OF TETRAHYDROBERBERINE (THB)

Dignity Health, Phoenix,...


1. A method of treating diabetes in a subject with diabetes, the method comprising the steps of:providing a quantity of a composition comprising tetrahydroberberine (THB) and Iptakalim (Ipt) or salts thereof; and
treating the subject by administering a therapeutically effective amount of the composition.

US Pat. No. 11,066,539

RUBBER COMPOSITION

KAO CORPORATION, Tokyo (...


1. A rubber composition comprising(A) 100 parts by mass of a rubber component,
(B) 1 part by mass to 30 parts by mass of a lignin degradation product having an aldehyde yield, according to an alkaline nitrobenzene oxidation method, of 12% by mass or more, and
(C) 0.1 part by mass to 10 parts by mass of an anti-aging agent.

US Pat. No. 11,069,886

NEGATIVE ELECTRODE FOR NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, AND METHOD FOR PRODUCING NEGATIVE ELECTRODE FOR NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

PANASONIC INTELLECTUAL PR...


1. A negative electrode for a nonaqueous electrolyte secondary battery, the negative electrode comprising a negative electrode current collector, a negative electrode active material layer provided on the surface of the negative electrode current collector, and a first film which has lithium ion permeability and which coats at least a portion of the surface of the negative electrode active material layer and partially coats the surface of the negative electrode current collector,wherein the first film contains a first lithium compound containing an element M1, an element A1, and lithium;
M1 is at least one selected from the group consisting of P, Si, B, V, Nb, W, Ti, Zr, Al, Ba, La, and Ta; and
A1 is at least one selected from the group consisting of F, S, O, N, and Br, and
wherein in the first film, the concentration of the first lithium compound is low on the surface side of the first film, and is high on the bond interface side between the first film and the negative electrode active material layer or on the bond interface side between the first film and the negative electrode current collector.

US Pat. No. 11,065,245

PRIMING OF CANCER CELLS WITH LOW DOSE NALTREXONE

Cancer Vaccine Institute,...


1. A method of treating a subject having colon cancer comprising administering to the subject in a first treatment phase naltrexone at a dose of between 0.01 mg/kg and 0.08 mg/kg, followed by a recovery phase; wherein, following the recovery phase, a small molecule signalling inhibitor selected from the group consisting of gemcitabine, cyclophosphamide and oxaliplatin is to be administered to the subject in a second treatment phase; the recovery phase being characterized by the absence of administration of the naltrexone and the small molecule signalling inhibitor wherein the colon cancer is treated.
US Pat. No. 11,066,540

RUBBER CRAWLER

BRIDGESTONE CORPORATION, ...


1. A rubber crawler comprising a guide rubber obtained by crosslinking a guide rubber composition and an inner peripheral rubber obtained by crosslinking an inner peripheral rubber composition,the guide rubber composition containing a rubber component (A) and a carbon black (B),
the rubber component (A) containing a butadiene rubber and at least one selected from a natural rubber and isoprene rubber, and containing 50 to 80% by mass in total of the natural rubber and the isoprene rubber and 20 to 50% by mass of the butadiene rubber,
the carbon black (B) containing a carbon black (B-1) having a nitrogen adsorption specific surface area of 60 to 125 m2/g and a dibutyl phthalate absorption of less than 130 mL/100 g, and a carbon black (B-2) having a nitrogen adsorption specific surface area of less than 60 m2/g and a dibutyl phthalate absorption of 110 mL/100 g or more, and
a total content of the carbon black (B-1) and the carbon black (B-2) is 25 to 65 parts by mass based on 100 parts by mass of the rubber component (A);
the inner peripheral rubber composition containing a rubber component (a) and a carbon black (b),
the rubber component (a) containing 60 to 100% by mass of a styrene-butadiene rubber and 0 to 40% by mass of a diene-based rubber other than the styrene-butadiene rubber, and
a content of the carbon black (b) is 50 to 70 parts by mass based on 100 parts by mass of the rubber component (a).

US Pat. No. 11,067,569

METHOD OF STABILIZING MOLECULES WITHOUT REFRIGERATION USING WATER SOLUBLE POLYMERS AND APPLICATIONS THEREOF IN PERFORMING CHEMICAL REACTIONS

MCMASTER UNIVERSITY, Ham...


1. A device comprising two or more reagents entrapped in the same solid polymeric structure or in separate solid polymeric structures wherein the solid polymeric structure or structures are prepared from an aqueous solution comprising about 10% (w/v) to about 13% (w/v) of pullulan and at least one of the two or more reagents is selected from one or more different reagents that are a protein, antibody, peptide, nucleic acid, phage, antidote and vaccine, or at least one of the two or more reagents is a material from a microorganism, or at least one of the two or more reagents is an inorganic or an organic molecule.
US Pat. No. 11,065,246

GLUCOMANNAN CONTAINING PHARMACEUTICAL COMPOSITIONS WITH EXTENDED RELEASE AND ABUSE DETERRENT PROPERTIES

SpecGX LLC, Webster Grov...


1. A solid dosage form comprising an opioid or a pharmaceutically acceptable salt thereof, about 20-30% w/w of a glucomannan, about 35-45% w/w of a first polyethylene oxide having an average molecular weight of 100,000, about 18-24% w/w of a second polyethylene oxide having an average molecular weight of 2,000,000, about 0.01-0.3% w/w of an antioxidant, about 1-3% w/w of a lubricant, and an optional film coating.
US Pat. No. 11,066,541

MULTIMODAL POLYPROPYLENE COMPOSITION FOR PIPE APPLICATIONS

ABU DHABI POLYMERS COMPAN...


1. A multimodal polypropylene composition suitable for pipe applications, comprising:a multimodal propylene copolymer (U) that comprises:
(A) from 75 to 98 wt.-% of a propylene random copolymer composition (X) which comprises:i. from 40 to 53 wt.-% of a first propylene homopolymer or random copolymer (V) having an MFR2 of from 1.0 to 5.0 g/10 min; and
ii. from 47 to 60 wt.-% of a second propylene homopolymer or random copolymer (W), having an MFR2 of from 0.10 to 0.60 g/10 min;
iii. provided that at least one of said first propylene homopolymer or random copolymer (V) and said second propylene homopolymer or random copolymer (W) is a propylene random copolymer having a comonomer selected from at least one of the group consisting of ethylene and C4-C8 alpha-olefins; and

(B) from 2 to 25 wt.-% of a propylene copolymer (Y) having a melt flow rate MFR2 of 0.0001 to 0.1 g/10 min or a content of comonomer units of from 9.0 to 40.0 mole-% or both, wherein the comonomer is selected from at least one of the group consisting of ethylene and C4-C8 alpha-olefins;
(C) wherein the multimodal propylene copolymer (U) has at least one comonomer selected from the group consisting of ethylene and C4-C8 alpha-olefins in a total amount of 4.0 to 10.0 mole-%;
wherein the multimodal polypropylene composition has:i. a melt flow rate MFR2 (2.16 kg, 230° C.) of 0.35 to 1.00 g/10 min determined according to ISO 1133;
ii. a content of xylene cold solubles (XCS) of 6.0 to 13.5 wt.-% determined at 25° C. according to ISO 16152; and
iii. a polydispersity index PI of 2.5 to 4.0 Pa?1 determined by rheological measurements according to ISO 6721-1 and ISO 6721-10.


US Pat. No. 11,065,247

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER


1. A method of treating Zellweger spectrum disorder comprising Zellweger Syndrome (ZS), neonatal adrenoleukodystrophy, or Refsum disease (IRD), in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound selected from naltriben, naltrindole, or a tautomer of each thereof, or a pharmaceutically acceptable salt of each of the foregoing.
US Pat. No. 11,066,542

METHOD OF PREPARING THERMOPLASTIC RESIN, THERMOPLASTIC RESIN COMPOSITION INCLUDING THE SAME, AND METHOD OF MANUFACTURING INJECTION-MOLDED ARTICLE USING THERMOPLASTIC RESIN COMPOSITION

LG CHEM, LTD., Seoul (KR...


1. A method of preparing a thermoplastic resin, the method comprising emulsion-polymerizing an aromatic vinyl compound and a vinyl cyan compound, wherein a mixture of 20 to 54% by weight of mercaptan and 46 to 80% by weight of an alpha-alkyl styrene multimer is used as a molecular weight modifier,wherein the emulsion polymerizing comprises:
i) a polymerization step of polymerizing 100 parts by weight of a monomer mixture comprising 50 to 80% by weight of the aromatic vinyl compound and 20 to 50% by weight of the vinyl cyan compound, 0.05 to 1 part by weight of the molecular weight modifier, 0.01 to 1 part by weight of an initiator, and 0.1 to 3 parts by weight of an emulsifier;
ii) a termination step of terminating the polymerization step when a conversion rate in the polymerization step is 90% or more; and
iii) a coagulation step of adding a 0.1 to 3 parts by weight of an acid coagulant to 100 parts by weight of a latex that is obtained after the termination step, followed by coagulation, and
iv) a dehydration and drying step of the coagulated slurry,
wherein the wet powder obtained after the dehydration has a water content of 45% by weight or less,
wherein the thermoplastic resin has a weight average molecular weight of 350,000 to 750,000 g/mol.

US Pat. No. 11,065,248

BUPROPION AS A MODULATOR OF DRUG ACTIVITY

ANTECIP BIOVENTURES II LL...


1. A method of enhancing dextromethorphan plasma levels in a human being, comprising co-administering a bupropion with a dextromethorphan, to the human being, twice daily for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein the weight ratio of the dextromethorphan to the bupropion is about 0.4 to about 0.7, wherein, on the eighth day that the bupropion and the dextromethorphan are co-administered, the AUC0-12 of dextromethorphan is at least about 15 times the AUC0-12 of dextromethorphan that would result from administering the same amount of the dextromethorphan twice daily without the bupropion for eight consecutive days, and wherein the AUC0-12 of dextromethorphan is at least about 800 ng·hr/mL.
US Pat. No. 11,065,508

GOLF BALL HAVING AT LEAST ONE LAYER CONSISTING OF A MIXTURE OF A THERMOSET OR THERMOPLASTIC COMPOSITION AND A PLURALITY OF ALKOXYLATED SILOXANE-SURFACE TREATED PARTICLES AND/OR POLYETHER-MODIFIED SILOXANE-SURFACE TREATED PARTICLES

Acushnet Company, Fairha...


1. A golf ball having a CoR of at least 0.700 and an Atti compression of at least about 50 and comprising at least one layer comprising a mixture of an ionomer composition and a plurality of particulates, wherein at least a portion of the plurality is surface-treated with alkoxylated siloxanes, polyether-modified siloxanes, or combinations thereof;wherein the particulates are selected from the group consisting of titanium dioxide particles, barium sulfate particles, zinc sulfide particles, zinc oxide particulates, or combinations thereof;
wherein the plurality of particulates is included in the mixture in an amount such that the at least one layer has a specific gravity of from 0.5 to about 5.0 and greater than a specific gravity of the ionomer composition; and
wherein the plurality of particulates creates a specific gravity gradient within the least one layer; and
wherein the at least one layer is an intermediate layer and/or a cover layer.

US Pat. No. 11,067,572

METHODS AND ASSAYS FOR FACTOR VIII ACTIVITY

President and Fellows of ...


1. A kit for measuring fVIII activity, the kit comprising:fibrin or fibrinogen;
a platelet membrane-comprising composition;
Factor IXa;
Factor X;
a solid support having monoclonal antibodies that specifically bind fVIII immobilized thereupon; and
packaging materials therefor.

US Pat. No. 11,065,509

GOLF BALL

SUMITOMO RUBBER INDUSTRIE...


1. A golf ball comprising a golf ball body and a paint film covering the golf ball body, whereinthe paint film is formed from a paint containing a base resin and a silicon-containing filler having a bulk density in a range from 0.2 g/cm3 to 1.0 g/cm3,
the silicon-containing filler is a porous filler,
the paint film contains the silicon-containing filler, and
a paint film surface of the golf ball has a water contact angle A1 of 70° or more and a water sliding angle B1 of less than 50°.

US Pat. No. 11,067,831

METHODS OF MANUFACTURING COATED CONTACT LENSES

COOPERVISION INTERNATIONA...


1. A method of manufacturing a coated contact lens comprising:a) providing a polymeric lens body comprising an acid group;
b) coating the polymeric lens body with a first coating polymer comprising an amine group, wherein a first portion of the amine group ionically binds to the acid group, and
c) contacting the first coating polymer with a second coating polymer comprising an amine-reactive group under conditions in which a second portion of the amine group on the first coating polymer covalently binds to the amine-reactive group.

US Pat. No. 11,069,891

BATTERY, BATTERY PACK AND CONTINUOUS POWER SUPPLY

POSITEC POWER TOOLS (SUZH...


1. A battery, comprising:a cathode, an anode and an electrolyte;
the cathode comprising a cathode current collector and a cathode material, and the cathode material comprising a cathode active material which is capable of reversibly intercalating and deintercalating a plurality of first metal ions;
the electrolyte comprising a solvent capable of dissolving the first metal ions and a plurality of second metal ions that can be reduced to a metal during a charge cycle and be oxidized from the metal to the dissolved second metal ions during a discharge cycle, with the first metal ions being different from the second metal ions;
the cathode current collector comprising an electrochemically inert carrier and graphite foil, the carrier being wrapped by the graphite foil,
wherein the material of the carrier is selected from one of polyethylene terephthalate, polybutylene terephthalate, polyethylene, polypropylene, polyamide, polyurethane and polyacrylonitrile,
wherein the carrier is provided with a porous structure and the pore size range of the carrier is between 50 meshes and 200 meshes, and
wherein the thickness of the carrier is less than 1 mm.

US Pat. No. 11,066,545

LUBRICIOUS STRUCTURES, METHODS OF MAKING THEM, AND METHODS OF USE

University of Florida Res...


1. A structure, comprising:a coating including a physically entangled polymer network, wherein each polymer has a plurality of coupling groups on the main backbone of polymer, wherein a mesh size of the physically entangled network of polymers is about 5.5 to 8 nm, and
a substrate having a surface, wherein there is a covalent bond between the surface of the substrate and one coupling group of the plurality of coupling groups.

US Pat. No. 11,069,892

ACTIVE MATERIAL FOR NEGATIVE ELECTRODE, NEGATIVE ELECTRODE PIECE, AND SECONDARY BATTERY

CONTEMPORARY AMPEREX TECH...


1. A negative electrode active material, comprising a chelating resin and a metal ion;the chelating resin comprising a polymer skeleton and a chelating functional group;
the chelating functional group being fixedly connected to the polymer skeleton via a chemical bond;
the metal ion being connected with the chelating resin by an ionic bond and/or a coordinate bond via the chelating functional group;
wherein,
the chelating resin further comprises iminodiacetic acid;
in the chelating resin, a mass percentage of iminodiacetic acid is less than or equal to 1%;
the metal ion is a divalent or multivalent metal ion.

US Pat. No. 11,066,546

GLYOXYLATED POLYACRYLAMIDE POLYMER COMPOSITION, ITS USE AND METHOD FOR INCREASING THE STRENGTH PROPERTIES OF PAPER, BOARD OR THE LIKE

Kemira Oyj, Helsinki (FI...


1. A cationic glyoxylated polyacrylamide polymer composition, comprising:a glyoxylated polyacrylamide polymer having a glyoxal to acrylamide unit molar ratio in a range of 0.50-0.65, a weight average molecular weight MW>250,000 g/mol, and a cationic charge density in a range of 0.8 meq/g-1.8 meq/g of dry polymer, in a dry content amount of 5%-15%;
an aqueous medium;
a buffering acid;
an unreacted glyoxal in an amount of below 1 weight-% by a total weight of the composition; and
the aqueous composition has a pH in a range of 2.2-4.0.

US Pat. No. 11,069,377

MAGNETIC TAPE HAVING CHARACTERIZED MAGNETIC LAYER AND MAGNETIC RECORDING AND REPRODUCING DEVICE

FUJIFILM Corporation, To...


1. A magnetic tape comprising a magnetic layer containing a ferromagnetic powder and a binding agent on a non-magnetic support,wherein the magnetic layer contains an oxide abrasive,
an average particle diameter of the oxide abrasive obtained from a secondary ion image acquired by irradiating a surface of the magnetic layer with a focused ion beam is 0.04 ?m to 0.08 ?m, and
an absolute value ?N of a difference between a refractive index Nxy measured with respect to an in-plane direction of the magnetic layer and a refractive index Nz measured with respect to a thickness direction of the magnetic layer is 0.25 to 0.40.

US Pat. No. 11,065,252

TREATMENT OF ROSACEA WITH P38 AND ERK KINASE PATHWAY INHIBITORS

Albany Medical College, ...


1. A method of treating rosacea, comprising the step of administering a pharmaceutically effective amount of trametinib to a subject having ocular rosacea.
US Pat. No. 11,066,547

THERMOPLASTIC RESIN COMPOSITION, AND MOLDED ARTICLE PRODUCED THEREFROM

Lotte Advanced Materials ...


1. A thermoplastic resin composition comprising:about 100 parts by weight of a thermoplastic resin comprising about 20 wt % to about 50 wt % of a rubber-modified vinyl graft copolymer and about 50 wt % to about 80 wt % of an aromatic vinyl copolymer;
a heat stabilizer comprising about 0.05 to about 2 parts by weight of a phenol-based heat stabilizer and about 0.05 to about 2 parts by weight of a phosphorus-based heat stabilizer; and
about 0.3 to about 10 parts by weight of zinc oxide having an average particle size of about 0.5 ?m to about 3 ?m and a BET specific surface area of about 1 m2/g to about 10 m2/g.

US Pat. No. 11,066,548

POLYPHENYLENE ETHER RESIN COMPOSITION, PREPREG, METAL-CLAD LAMINATE, AND PRINTED WIRING BOARD

PANASONIC INTELLECTUAL PR...


1. A polyphenylene ether resin composition comprising:a modified polyphenylene ether copolymer that is modified with a substituent having a carbon-carbon unsaturated double bond at a molecular chain end of a polyphenylene ether copolymer;
a high-molecular-weight compound having a number-average molecular weight Mn ranging from 1000 to 10000, inclusive and having a glass transition temperature (Tg) of 20° C. or lower, the glass transition temperature being measured by differential scanning calorimetry; and
a crosslinking agent for the modified polyphenylene ether copolymer, the crosslinking agent including at least two carbon-carbon unsaturated double bonds per molecule, wherein:
the crosslinking agent includes at least one of dicyclopentadiene acrylate and dicyclopentadiene methacrylate,
the high-molecular-weight compound includes a butadiene-styrene copolymer, and
the modified polyphenylene ether copolymer is phase separated from the high-molecular-weight compound in a cured state of the polyphenylene ether resin composition.

US Pat. No. 11,067,577

METHOD FOR DIAGNOSIS, PROGNOSIS AND DETERMINATION OF TREATMENT FOR CUTANEOUS T-CELL LYMPHOMA


1. A method of normalizing the expression of TOX, PLS3, and RUNX3 genes in a subject suffering from cutaneous T-cell lymphoma (CTCL) in need thereof, the method comprising:(a) obtaining a biological sample from a subject suffering from CTCL;
(b) measuring a first expression level of the biomarkers TOX, PLS3, and RUNX3 in the biological sample;
(c) identifying the subject suffering from CTCL as a subject in need thereof based on the detection of the expression level of TOX being more than 5 fold, the expression level of PLS3 being more than 10 fold, and the expression level of RUNX3 being less than about 60% relative to the expression levels of TOX, PLS3 and RUNX3 in a subject who does not suffer from CTCL;
(d) contacting the biological sample of said subject identified in step (c) with a therapeutic agent for the treatment of CTCL;
(e) measuring a second expression level of the biomarkers TOX, PLS3 and RUNX3 in the biological sample;
(f) identifying the subject as likely to have a response to the therapeutic agent based on the detection of:(1) the second expression levels of TOX and PLS3 being decreased as compared to the first expression levels of TOX and PLS3; and
(2) the second expression level of RUNX3 being increased as compared to the first expression level of RUNX3; and

(g) administering to said subject the therapeutic agent, thereby normalizing the expression of TOX, PLS3, and RUNX3 genes in said subject.

US Pat. No. 11,067,835

METHOD FOR PRODUCING TRANSPARENT CERAMIC,TRANSPARENT CERAMIC, MAGNETO-OPTICAL DEVICE AND RARE EARTH OXIDE POWDER FOR SINTERING

SHIN-ETSU CHEMICAL CO., L...


1. A rare earth oxide powder for sintering containing a rare earth oxide including terbium oxide and at least one other rare earth oxide selected from among yttrium oxide, scandium oxide and oxides of lanthanide rare earth elements excluding terbium, the molar ratio of terbium oxide being at least 40 mol % and the balance being the other rare earth oxide, and a sintering aid including an oxide of at least one element selected from among Group 2 elements and Group 4 elements, the rare earth oxide powder obtained by subjecting an aqueous solution containing (a) terbium ions, (b) ions of at least one other rare earth element selected from among yttrium ions, scandium ions and lanthanide rare earth ions excluding terbium ions and (c) ions of at least one element selected from among Group 2 elements and Group 4 elements to co-precipitation of the components (a), (b) and (c), filtration and separation of the co-precipitate and thermal dehydration, wherein the rare earth oxide powder is a three-component co-precipitated raw material for producing a transparent ceramic.
US Pat. No. 11,069,637

SEMICONDUCTOR DEVICE, MANUFACTURING METHOD, AND ELECTRONIC DEVICE

SONY SEMICONDUCTOR SOLUTI...


1. A semiconductor device, comprising:a first Cu electrode pad configured to bond a first semiconductor member of a plurality of semiconductor members to a second semiconductor member of the plurality of semiconductor members;
a lower-layer metal; and
an electrode via configured to connect the first Cu electrode pad to the lower-layer metal, whereinthe first Cu electrode pad is in a location displaced from the electrode via,
an entirety of the first Cu electrode pad is in a non-overlapping arrangement with the electrode via,
the electrode via includes an electrically conductive metal, other than Cu, on each of a first side wall of the electrode via and a second side wall of the electrode via, and
a space between the electrically conductive metal on the first side wall and the electrically conductive metal on the second side wall includes an insulating film.


US Pat. No. 11,067,578

TN-MUC4 BINDING POLYPEPTIDES AND USES THEREOF

GO Therapeutics, Inc., C...


1. A Tn-MUC4 binding polypeptide comprising the six complementarity determining regions (CDRs) of the monoclonal antibody produced by the cell line 4D9 deposited with the European Collection of Authenticated Cell Cultures (ECACC) under accession number 09120102.
US Pat. No. 11,065,255

CRYSTALLINE FORM OF (S)-[2-CHLORO-4-FLUORO-5-(7-MORPHOLIN-4-YL-QUINAZOLIN-4-YL)PHENYL]-(6-METHOXY-PYRIDAZIN-3-YL)-METHANOL

Merck Patent GmbH, Darms...


1. A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol.
US Pat. No. 11,066,550

POLYETHER-EPOXIDE POLYMER COMPOSITIONS

STEPAN COMPANY, Northfie...


11. The elastomer or microcellular elastomer of claim 10 wherein the polyether polyol comprises a sucrose-initiated polyether polyol and the elastomer has a Shore A hardness of at least 90, a peak tensile stress of at least 1000 psi, and a modulus of at least 25,000 psi.
US Pat. No. 11,067,579

TARGET MARKER GP73 FOR DETECTING STEATOHEPATITIS AND DETECTION APPLICATION METHOD

BEIJING DITAN HOSPITAL CA...


1. A method for treating a human subject suffering from steatohepatitis, the method comprising:measuring a target marker GP73 in a blood sample to be tested from the human subject;
comparing a measured value of the target marker GP73 in the sample to be tested with a standard value of the target marker GP73 thereof, the standard value being able to identify and diagnose steatohepatitis in populations with fatty liver;
identifying the human subject as suffering from a simple fatty liver in response to the measured value of the target marker GP73 in the sample to be tested is less than the standard value of the target marker GP73; and
treating the human subject suffering from steatohepatitis with an anti-GP73 protein antibody.

US Pat. No. 11,066,551

ORIENTED POLYLACTIC ACID POLYMER BASED FILM

3M Innovative Properties ...


1. A film comprising a mixture of50 to 80 wt.-% of semicrystalline polylactic acid polymer(s);
5 to 40 wt.-% of polyvinyl acetate polymer having a glass transition temperature (Tg) midpoint, as measured by differential scanning calorimetry, of at least 25° C.; and
1 to 20 wt.-% plasticizer; and
wherein the film is oriented and the dielectric loss tangent at 1 kHz is at least 0.007.

US Pat. No. 11,067,582

PEPTIDE ARRAY QUALITY CONTROL

Arizona Board of Regents ...


1. A method for determining quality and fidelity of an in situ synthesized immunosignature array, wherein the in situ synthesized immunosignature array comprises an array of peptides, the method comprising:obtaining a specific binding strength of each peptide of the in situ synthesized immunosignature array, wherein the specific binding strength is obtained from binding with a first sample, the first sample comprising a biological sample from a subject;
obtaining a background binding pattern of an immunosignature reference array, wherein the background binding pattern is represented by a mean binding strength of empty control regions in the immunosignature reference array; and
measuring a standard deviation of the specific binding strength of each peptide compared to the background binding pattern, wherein a measurement of more than three standard deviations establishes synthesis quality and fidelity of the in situ synthesized immunosignature array.

US Pat. No. 11,067,583

METHODS OF MAKING ACTIVE ANTIBODIES FROM BIOLOGICAL FLUIDS

UNIVERSITY OF MARYLAND, B...


1. A method of making an antibody by identifying a circulating antibody with activity from a subject comprising:i) subjecting biological fluid selected from the group consisting of blood, plasma and serum and combinations thereof from the subject to one or more rounds of affinity chromatography to purify the circulating antibody;
ii) optionally further subjecting the circulating antibody to isoelectric focusing to purify the circulating antibody based on charge;
iii) testing the purified circulating antibody for activity;
iv) digesting the purified circulating antibody from parts i) or ii) to create an antibody fragment;
v) subjecting the antibody fragment to mass spectrometry to generate a mass assignment and a deduced amino acid sequence of the antibody fragment;
vi) comparing the deduced amino acid sequence with an amino acid sequence of an antibody generated from the subject's B-cells to identify an antibody sequence that matches the deduced amino acid sequence;
vii) generating an antibody comprising light chain and heavy chain CDR sequences of the B-cell antibody that matches the deduced amino acid sequence of part vi); and
viii) testing the antibody of part vii) for activity;wherein the circulating antibody with activity binds an HIV antigen selected from the group consisting of gp120, p24, gp41, p31, p17, p55, RT, rev, nef, vpu, and tat; and
wherein the B-cells comprise bone marrow cells exhibiting a long or short-lived phenotype, wherein the B-cells have a phenotype that is CD38hi, CD19+ or CD19?, and CD138+ or CD138?.


US Pat. No. 11,065,260

METHOD OF TREATMENT FOR REDUCING PULMONARY INFLAMMATION IN A PATIENT WITH PATHOGEN INFECTION USING ORAL PROSTACYCLIN ANALOG DRUGS


1. A method of treating a human patient having a corona virus strain infection in order to reduce progression of the corona virus strain infection in the human patient, the method comprising:determining whether the corona virus strain consists essentially of Covid-19, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), MERS-CoV or SARS-CoV;
then determining a stage of severity of the corona virus infection in the human patient;
if the stage of severity is moderate to severe then administering an oral dose of iloprost or iloprost betadex clathrate to the human patient within a therapeutic window;
wherein the oral dose of iloprost or iloprost betadex clathrate is substantially in a range of 50-150 micrograms administered twice daily; and
maintaining the human patient within a defined therapeutic range.

US Pat. No. 11,067,584

METHODS FOR THE QUANTITATION OF POLYPEPTIDES

Genzyme Corporation, Cam...


1. A method for quantitating an amount of a polypeptide comprising a portion of an antibody heavy chain constant region in a sample comprising:(a) digesting the sample comprising the polypeptide comprising the portion of the antibody heavy chain constant region, wherein the portion of the antibody heavy chain constant region comprises an engineered mutation, and wherein digestion produces a peptide fragment derived from the antibody heavy chain constant region that is between 5 and 26 amino acids long and comprises the engineered mutation,
(b) analyzing the digested sample by mass spectrometry to determine quantity of the peptide fragment, thereby determining the quantity of the polypeptide comprising the portion of the antibody heavy chain constant region in the sample.

US Pat. No. 11,067,585

METHOD FOR MONITORING CANCER AND/OR INFLAMMATORY REACTION BASED ON RELB PHOSPHORYLATION

CENTRE NATIONAL DE LA REC...


1. The monoclonal antibody produced by hybridoma RA3-AF3, deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) at the Institut Pasteur, 25, Rue du Docteur Roux, 75724 Paris, FR, on Nov. 18, 2020, under the deposit number CNCM 1-5612.
US Pat. No. 11,065,262

TOPICAL TREATMENT OF WOUNDS WITH STATINS AND CHOLESTEROL FOR SCAR REDUCTION

Northwestern University, ...


1. A method of preventing or reducing scar formation in the skin of a subject during wound healing comprising:administering a composition topically to a wound site of a subject such that scar tissue formation in said skin is reduced or prevented during wound healing,
wherein said administering occurs at least two weeks after said wound site is generated and is repeated daily for at least one week,
wherein said composition comprises:
i) a pharmaceutically acceptable carrier,
ii) a statin at a concentration of 6-10% of said pharmaceutically acceptable carrier, and
iii) cholesterol, cholesterol derivative, or cholesterol analog at 1-15% of said pharmaceutically acceptable carrier.

US Pat. No. 11,067,586

ADRENOMEDULLIN ASSAYS AND METHODS FOR DETERMINING MATURE ADRENOMEDULLIN

SPHINGOTEC GMBH, Hennigs...


1. An in vitro method for therapy follow-up comprising providing a plasma or whole blood sample from a human patient suspected of having sepsis and detecting the concentration of mature adrenomedullin (ADM) 1-52 and/or mature ADM 1-52-Gly in said sample of plasma or whole blood of said septic human patient using an assay comprising two antibodies that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is SEQ ID No. 1 or SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acidsand wherein a threshold value for the concentration of mature adrenomedullin (ADM) 1-52 and/or mature ADM 1-52-Gly from 60 to 80 pg/ml is applied, whereby a value below said threshold is indicative of a human patient responding to therapy and a value above said threshold is indicative of a human patient that is not responding to therapy.

US Pat. No. 11,064,749

SYNTHETIC ELASTOMERIC ARTICLE AND METHOD FOR THE PRODUCTION THEREOF

SKINPROTECT CORPORATION S...


1. An elastomeric article comprising:an elastomeric film comprising one or more film layers, and including an external surface and an internal surface,
an antimicrobial agent that is effective against both beneficial and harmful microorganisms on the external surface of the elastomeric film,
a dry, dehydrated coating layer on the internal surface of the elastomeric film comprising a skin-protective agent selected from a probiotic, a prebiotic, or a combination thereof, and
a barrier film layer that provides separation between the antimicrobial agent and the skin-protective agent and substantially prevents migration of the antimicrobial agent to the internal surface of the elastomeric film,
wherein the internal surface of the elastomeric film is free of an antimicrobially-effective amount of an antimicrobial agent that is effective against both beneficial and harmful microorganisms.

US Pat. No. 11,065,263

STEROL COMPOSITION IN PUMPKIN SEED OIL AND APPLICATION THEREOF, AND DRUG FOR TREATING BENIGN PROSTATIC HYPERPLASIA

Hunan Zhongkewentai Bio-t...


1. A method for preparing a sterol composition from pumpkin seed oil comprising:a) preparing 0.5-1.5 mol/L of a potassium hydroxide-ethanol solution; combining the pumpkin seed oil and the potassium hydroxide-ethyl alcohol solution with a solid-liquid ratio of 1:10 (w:v); saponifying under reflux at 65° C.-100° C. for 0.5-2.5 hours; after finishing saponifying, obtaining a mixed liquid; adding water into the mixed liquid, wherein a volume fraction of water is 12.5%-25% of that of the mixed liquid; dissolving the fatty acid salt generated by saponification; cooling the reaction system to a room temperature, and obtaining a saponification liquid,
b) washing the saponification liquid successively with water, an ethanol-water solution, water, potassium hydroxide solution and water; removing the lower aqueous phase of the saponification liquid and keeping the upper organic phase of the saponification liquid;
c) taking the upper phase of the saponification liquid;
d) washing the upper phase, drying and then crystallizing the upper phase to obtain the sterol composition from the pumpkin seed oil, wherein the sterol composition from the pumpkin seed oil comprises 0.2 wt. %-2 wt. % cholesterol, 0.5 wt. %-5 wt. % campesterol, 1.5 wt. %-5 wt. % B-sitosterol, 15 wt. %-40 wt. % stigmasterol, 20 wt. %-40 wt. % ergosta-7,22-dien-3 beta-ol, 5 wt. %-10 wt. % lanosterol and 15 wt. %-30 wt. % cholest-7-en-3 beta,5 alpha-diol.

US Pat. No. 11,066,558

ASPHALT COMPOSITION, METHOD FOR PRODUCING SAME AND ADDITIVE FOR ASPHALT

KAO CORPORATION, Tokyo (...


1. An asphalt composition comprising asphalt and cellulose, whereinthe content of the cellulose is 0.01 part by mass or more and 10 parts by mass or less based on 100 parts by mass of the asphalt, and
a crystallization index of the cellulose is 50% or less.